Titan Biotech Share Price
Sector: Biotechnology & Drugs
You have to be logged in to add this to Watchlist.
Login or Register
757.00 -11.70 (-1.52%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
745.1
Today’s High
793
52 Week Low
375
52 Week High
1017.85
Key Metrics
- Market Cap (In Cr) 635.23
- Beta 0.08
- Div. Yield (%) 0.26
- P/B 4.76
- TTM P/E 23.22
- Peg Ratio -3.91
- Sector P/E 24.11
- D/E 0.02
- Open Price 771.05
- Prev Close 768.7
Titan Biotech Analysis
Price Analysis
-
1 Week-12.38%
-
3 Months31.62%
-
6 Month53.59%
-
YTD87.67%
-
1 Year94.73%
Risk Meter
- 59% Low risk
- 59% Moderate risk
- 59% Balanced Risk
- 59% High risk
- 59% Extreme risk
Titan Biotech Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 164.07
- Selling/ General/ Admin Expenses Total
- 23.71
- Depreciation/ Amortization
- 3.33
- Other Operating Expenses Total
- 30.47
- Total Operating Expense
- 133.12
- Operating Income
- 30.95
- Net Income Before Taxes
- 31.53
- Net Income
- 24.85
- Diluted Normalized EPS
- 30.07
- Period
- 2024
- Total Assets
- 156.58
- Total Liabilities
- 23.13
- Total Equity
- 133.45
- Tangible Book Valueper Share Common Eq
- 161.38
- Period
- 2024
- Cashfrom Operating Activities
- 21.15
- Cashfrom Investing Activities
- -20.3
- Cashfrom Financing Activities
- -2.87
- Net Changein Cash
- -2.02
- Period
- 2023
- Total Revenue
- 144
- Selling/ General/ Admin Expenses Total
- 30.99
- Depreciation/ Amortization
- 2.6
- Other Operating Expenses Total
- 0.13
- Total Operating Expense
- 117.08
- Operating Income
- 26.92
- Net Income Before Taxes
- 28.12
- Net Income
- 24.84
- Diluted Normalized EPS
- 30.06
- Period
- 2023
- Total Assets
- 134.52
- Total Liabilities
- 24.6
- Total Equity
- 109.91
- Tangible Book Valueper Share Common Eq
- 132.9
- Period
- 2023
- Cashfrom Operating Activities
- 21.18
- Cashfrom Investing Activities
- -20.73
- Cashfrom Financing Activities
- -2.4
- Net Changein Cash
- -1.95
- Period
- 2022
- Total Revenue
- 123.55
- Selling/ General/ Admin Expenses Total
- 23.59
- Depreciation/ Amortization
- 2.37
- Other Operating Expenses Total
- 0.16
- Total Operating Expense
- 94.65
- Operating Income
- 28.9
- Net Income Before Taxes
- 28.97
- Net Income
- 21.68
- Diluted Normalized EPS
- 26.24
- Period
- 2022
- Total Assets
- 108.09
- Total Liabilities
- 21.85
- Total Equity
- 86.24
- Tangible Book Valueper Share Common Eq
- 104.24
- Period
- 2022
- Cashfrom Operating Activities
- 22.04
- Cashfrom Investing Activities
- -16.44
- Cashfrom Financing Activities
- -4.1
- Net Changein Cash
- 1.51
- Period
- 2021
- Total Revenue
- 142.24
- Selling/ General/ Admin Expenses Total
- 31.54
- Depreciation/ Amortization
- 2.22
- Total Operating Expense
- 98.65
- Operating Income
- 43.59
- Net Income Before Taxes
- 42.71
- Net Income
- 30.34
- Diluted Normalized EPS
- 37
- Period
- 2021
- Total Assets
- 100.72
- Total Liabilities
- 31.96
- Total Equity
- 68.76
- Tangible Book Valueper Share Common Eq
- 83.09
- Period
- 2021
- Cashfrom Operating Activities
- 19.08
- Cashfrom Investing Activities
- -4.86
- Cashfrom Financing Activities
- -10.6
- Net Changein Cash
- 3.62
- Period
- 2020
- Total Revenue
- 79.44
- Selling/ General/ Admin Expenses Total
- 26.61
- Depreciation/ Amortization
- 1.8
- Total Operating Expense
- 67.14
- Operating Income
- 12.3
- Net Income Before Taxes
- 10.4
- Net Income
- 7.07
- Diluted Normalized EPS
- 8
- Period
- 2020
- Total Assets
- 76.04
- Total Liabilities
- 36.85
- Total Equity
- 39.19
- Tangible Book Valueper Share Common Eq
- 47.31
- Period
- 2020
- Cashfrom Operating Activities
- 6.12
- Cashfrom Investing Activities
- -2.21
- Cashfrom Financing Activities
- -3.95
- Net Changein Cash
- -0.04
- Period
- 2019
- Total Revenue
- 64.91
- Selling/ General/ Admin Expenses Total
- 23.28
- Depreciation/ Amortization
- 1.71
- Total Operating Expense
- 57.7
- Operating Income
- 7.21
- Net Income Before Taxes
- 5.54
- Net Income
- 3.52
- Diluted Normalized EPS
- 4.32
- Period
- 2019
- Total Assets
- 64.73
- Total Liabilities
- 32.55
- Total Equity
- 32.18
- Tangible Book Valueper Share Common Eq
- 38.82
- Period
- 2019
- Cashfrom Operating Activities
- 5.47
- Cashfrom Investing Activities
- -4.11
- Cashfrom Financing Activities
- -0.22
- Net Changein Cash
- 1.14
- Period
- 2018
- Total Revenue
- 57.37
- Selling/ General/ Admin Expenses Total
- 18.62
- Depreciation/ Amortization
- 0.93
- Total Operating Expense
- 51.33
- Operating Income
- 6.04
- Net Income Before Taxes
- 4.1
- Net Income
- 2.54
- Diluted Normalized EPS
- 3.29
- Period
- 2018
- Total Assets
- 56.81
- Total Liabilities
- 32.46
- Total Equity
- 24.36
- Tangible Book Valueper Share Common Eq
- 31.23
- Period
- 2018
- Cashfrom Operating Activities
- 1.9
- Cashfrom Investing Activities
- -5.57
- Cashfrom Financing Activities
- 0.23
- Net Changein Cash
- -3.44
- Period
- 2024-09-30
- Total Revenue
- 39.89
- Selling/ General/ Admin Expenses Total
- 6.5
- Depreciation/ Amortization
- 1.1
- Other Operating Expenses Total
- 8.12
- Total Operating Expense
- 33.23
- Operating Income
- 6.66
- Net Income Before Taxes
- 6.72
- Net Income
- 6.7
- Diluted Normalized EPS
- 8.1
- Period
- 2024-09-30
- Total Assets
- 173.1
- Total Liabilities
- 28.12
- Total Equity
- 144.98
- Tangible Book Valueper Share Common Eq
- 175.33
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 10.38
- Cashfrom Investing Activities
- 2.75
- Cashfrom Financing Activities
- -7.92
- Net Changein Cash
- 5.22
- Period
- 2024-06-30
- Total Revenue
- 43.11
- Selling/ General/ Admin Expenses Total
- 6.27
- Depreciation/ Amortization
- 1.05
- Other Operating Expenses Total
- 6.83
- Total Operating Expense
- 35.91
- Operating Income
- 7.2
- Net Income Before Taxes
- 7.52
- Net Income
- 6.4
- Diluted Normalized EPS
- 7.74
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 39.92
- Selling/ General/ Admin Expenses Total
- 6.8
- Depreciation/ Amortization
- 0.84
- Other Operating Expenses Total
- 7.75
- Total Operating Expense
- 33.68
- Operating Income
- 6.24
- Net Income Before Taxes
- 6.37
- Net Income
- 5
- Diluted Normalized EPS
- 6.05
- Period
- 2024-03-31
- Total Assets
- 156.58
- Total Liabilities
- 23.13
- Total Equity
- 133.45
- Tangible Book Valueper Share Common Eq
- 161.38
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 21.15
- Cashfrom Investing Activities
- -20.3
- Cashfrom Financing Activities
- -2.87
- Net Changein Cash
- -2.02
- Period
- 2023-12-31
- Total Revenue
- 45.98
- Selling/ General/ Admin Expenses Total
- 6.02
- Depreciation/ Amortization
- 0.83
- Other Operating Expenses Total
- 7.82
- Total Operating Expense
- 36.21
- Operating Income
- 9.77
- Net Income Before Taxes
- 9.94
- Net Income
- 7.17
- Diluted Normalized EPS
- 8.68
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 43.43
- Selling/ General/ Admin Expenses Total
- 5.47
- Depreciation/ Amortization
- 0.86
- Other Operating Expenses Total
- 8.03
- Total Operating Expense
- 35.57
- Operating Income
- 7.85
- Net Income Before Taxes
- 8.13
- Net Income
- 6.52
- Diluted Normalized EPS
- 7.89
- Period
- 2023-09-30
- Total Assets
- 147.79
- Total Liabilities
- 26.66
- Total Equity
- 121.14
- Tangible Book Valueper Share Common Eq
- 146.5
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 8.27
- Cashfrom Investing Activities
- -6.57
- Cashfrom Financing Activities
- -2
- Net Changein Cash
- -0.3
- Period
- 2023-06-30
- Total Revenue
- 34.75
- Selling/ General/ Admin Expenses Total
- 5.42
- Depreciation/ Amortization
- 0.8
- Other Operating Expenses Total
- 6.88
- Total Operating Expense
- 27.66
- Operating Income
- 7.09
- Net Income Before Taxes
- 7.09
- Net Income
- 6.16
- Diluted Normalized EPS
- 7.47
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 36.84
- Selling/ General/ Admin Expenses Total
- 5.22
- Depreciation/ Amortization
- 0.71
- Other Operating Expenses Total
- 7.41
- Total Operating Expense
- 30.71
- Operating Income
- 6.12
- Net Income Before Taxes
- 6.36
- Net Income
- 4.95
- Diluted Normalized EPS
- 5.99
- Period
- 2023-03-31
- Total Assets
- 134.52
- Total Liabilities
- 24.6
- Total Equity
- 109.91
- Tangible Book Valueper Share Common Eq
- 132.9
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 21.18
- Cashfrom Investing Activities
- -20.73
- Cashfrom Financing Activities
- -2.4
- Net Changein Cash
- -1.95
- Period
- 2022-12-31
- Total Revenue
- 30.33
- Selling/ General/ Admin Expenses Total
- 4.67
- Depreciation/ Amortization
- 0.65
- Other Operating Expenses Total
- 7.6
- Total Operating Expense
- 26.84
- Operating Income
- 3.49
- Net Income Before Taxes
- 3.63
- Net Income
- 3.26
- Diluted Normalized EPS
- 3.95
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Titan Biotech Technical
Moving Average
SMA
- 5 Day805.34
- 10 Day852.31
- 20 Day878.73
- 50 Day792.77
- 100 Day691.61
- 300 Day609.32
Titan Biotech Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Wanbury
- 211
- -11
- -4.95
- 291
- 91
- 690.93
- Albert David
- 1296
- 0.4
- 0.03
- 1752.95
- 912.1
- 739.65
- Titan Biotech
- 757
- -11.7
- -1.52
- 1017.85
- 375
- 625.56
- Medicamen Biotech
- 434.05
- -15.05
- -3.35
- 661.85
- 356.75
- 551.88
- Vikram Thermo India
- 174.5
- 0.05
- 0.03
- 218.67
- 112.64
- 547.19
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Wanbury
- 24.51
- 26.31
- -
- 7.62
- Albert David
- 9.67
- 1.92
- 13.89
- 11.87
- Titan Biotech
- 25.56
- 4.76
- 28.11
- 16.21
- Medicamen Biotech
- 51.91
- 2.75
- 8.92
- 9.58
- Vikram Thermo India
- 21.62
- 4.82
- 19.44
- 15.28
Titan Biotech Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 12-Nov-24
- Quarterly Results
- 13-Aug-24
- Quarterly Results
- 29-May-24
- Audited Results
- 12-Feb-24
- Quarterly Results
- 08-Nov-23
- Quarterly Results
- 10-Aug-23
- Quarterly Results
- 29-May-23
- Audited Results & Final Dividend
- 04-Feb-23
- Quarterly Results
- 14-Nov-22
- Quarterly Results
- 10-Aug-22
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 30-Sept-24
- 20-Sept-24
- AGM
- 29-Sept-23
- 06-Sept-23
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 29-May-24
- -
- 23-Sept-24
- 2
- 06-Sept-23
- -
- 22-Sept-23
- 1.8
- 01-Jun-22
- -
- 22-Sept-22
- 1.5
- 01-Jul-21
- -
- 16-Sept-21
- 1.5